{
    "Rank": 1051,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00031564",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "MCC-12207"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "NCI-5090",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "NCI"
                        },
                        {
                            "SecondaryId": "NCI-G00-1872",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "NCI"
                        },
                        {
                            "SecondaryId": "0001386",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "OBA"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "H. Lee Moffitt Cancer Center and Research Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2",
                "OfficialTitle": "Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 for Patients With Stage IV Renal Cell Carcinoma"
            },
            "StatusModule": {
                "StatusVerifiedDate": "September 2012",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "May 2000"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 2005",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "June 2012",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "March 8, 2002",
                "StudyFirstSubmitQCDate": "January 26, 2003",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "January 27, 2003",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "September 26, 2012",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "September 27, 2012",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "H. Lee Moffitt Cancer Center and Research Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        },
                        {
                            "CollaboratorName": "Chiron Corporation",
                            "CollaboratorClass": "INDUSTRY"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining vaccine therapy with interleukin-2 may kill more tumor cells.\n\nPURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have stage IV kidney cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nDetermine the percentage of patients with stage IV renal cell carcinoma with a reduction in tumor size after treatment with B7-1 gene-modified autologous tumor cell vaccine and interleukin-2.\nDetermine the immunogenicity of this regimen in these patients.\nDetermine the overall survival of patients treated with this regimen.\nDetermine the local and systemic toxicity of this regimen in these patients.\n\nOUTLINE: Tumor tissue for vaccine preparation is obtained when patients undergo palliative surgical resection of primary tumor or therapeutic resection of metastasis.\n\nAt approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.\n\nPatients are followed at 3 weeks after the last dose of IL-2.\n\nPROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Kidney Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage IV",
                        "renal cell carcinoma"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "49",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Vaccine Therapy With Interleukin-2",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: Interleukin-2",
                                    "Biological: B7-1"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "Interleukin-2",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Vaccine Therapy With Interleukin-2"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Aldesleukin",
                                    "IL-2"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "B7-1",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Vaccine Therapy With Interleukin-2"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "gene-modified autologous tumor cell vaccine"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Percentage of Patients Who Have a Reduction in the Size of Their Measurable Metastatic Tumors",
                            "PrimaryOutcomeDescription": "The primary objective of this phase II trial involving 30 patients will be to determine tumor response rates. The immunogenicity of the treatment will be assessed by ELISPOT assays performed on the patients' peripheral blood lymphocytes, and by an immunohistochemical analysis of DTH skin tests site biopsies performed 48 hours after the intradermal injection of autologous, unmodified tumor cells.",
                            "PrimaryOutcomeTimeFrame": "4 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed stage IV renal cell carcinoma\n\nSymptomatic primary tumor or resectable metastasis\nMeasurable disease post resection\nNo symptomatic brain metastases\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n18 and over\n\nPerformance status:\n\nEastern Cooperative Oncology Group (ECOG) 0-1\n\nLife expectancy:\n\nNot specified\n\nHematopoietic:\n\nWBC greater than 4,000/mm^3\nPlatelet count greater than 100,000/mm^3\nHemoglobin greater than 10 g/dL\nHematocrit greater than 30%\n\nHepatic:\n\nBilirubin less than 2 times normal\nSGOT less than 3 times normal\n\nRenal:\n\nCreatinine less than 1.5 mg/dL OR\nCreatinine clearance greater than 60 mL/min\n\nCardiovascular:\n\nNo evidence of active myocardial ischemia, prior myocardial infarction, or arrhythmia\n\nOther:\n\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNo contraindications to surgical resection\nNo history of immunodeficiency disease\nNo known allergy to penicillin\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\nPrior interleukin-2, interferon alfa, or other biologic agent allowed\n\nChemotherapy:\n\nNot specified\n\nEndocrine therapy:\n\nNo concurrent corticosteroids (except for replacement doses for adrenal insufficiency)\n\nRadiotherapy:\n\nNot specified\n\nSurgery:\n\nSee Disease Characteristics\n\nOther:\n\nNo concurrent immunosuppressants",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Scott J. Antonia, M.D., Ph.D.",
                            "OverallOfficialAffiliation": "H. Lee Moffitt Cancer Center and Research Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "H. Lee Moffitt Cancer Center and Research Institute",
                            "LocationCity": "Tampa",
                            "LocationState": "Florida",
                            "LocationZip": "33612",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "18157014",
                            "ReferenceType": "result",
                            "ReferenceCitation": "Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother. 2008 Jan;31(1):72-80. doi: 10.1097/CJI.0b013e31815ba792."
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000007680",
                            "ConditionMeshTerm": "Kidney Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000014571",
                            "ConditionAncestorTerm": "Urologic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000052776",
                            "ConditionAncestorTerm": "Female Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005261",
                            "ConditionAncestorTerm": "Female Urogenital Diseases and Pregnancy Complications"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000007674",
                            "ConditionAncestorTerm": "Kidney Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000014570",
                            "ConditionAncestorTerm": "Urologic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000052801",
                            "ConditionAncestorTerm": "Male Urogenital Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5238",
                            "ConditionBrowseLeafName": "Carcinoma, Renal Cell",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10393",
                            "ConditionBrowseLeafName": "Kidney Neoplasms",
                            "ConditionBrowseLeafAsFound": "Kidney Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M17010",
                            "ConditionBrowseLeafName": "Urologic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26783",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M13817",
                            "ConditionBrowseLeafName": "Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8089",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases and Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10388",
                            "ConditionBrowseLeafName": "Kidney Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17009",
                            "ConditionBrowseLeafName": "Urologic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26785",
                            "ConditionBrowseLeafName": "Male Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T4906",
                            "ConditionBrowseLeafName": "Renal Cell Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T1341",
                            "ConditionBrowseLeafName": "Clear Cell Renal Cell Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "C000082598",
                            "InterventionMeshTerm": "Aldesleukin"
                        },
                        {
                            "InterventionMeshId": "D000007376",
                            "InterventionMeshTerm": "Interleukin-2"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018712",
                            "InterventionAncestorTerm": "Analgesics, Non-Narcotic"
                        },
                        {
                            "InterventionAncestorId": "D000000700",
                            "InterventionAncestorTerm": "Analgesics"
                        },
                        {
                            "InterventionAncestorId": "D000018689",
                            "InterventionAncestorTerm": "Sensory System Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018373",
                            "InterventionAncestorTerm": "Peripheral Nervous System Agents"
                        },
                        {
                            "InterventionAncestorId": "D000019380",
                            "InterventionAncestorTerm": "Anti-HIV Agents"
                        },
                        {
                            "InterventionAncestorId": "D000044966",
                            "InterventionAncestorTerm": "Anti-Retroviral Agents"
                        },
                        {
                            "InterventionAncestorId": "D000000998",
                            "InterventionAncestorTerm": "Antiviral Agents"
                        },
                        {
                            "InterventionAncestorId": "D000000890",
                            "InterventionAncestorTerm": "Anti-Infective Agents"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M225435",
                            "InterventionBrowseLeafName": "Aldesleukin",
                            "InterventionBrowseLeafAsFound": "Internal",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M10101",
                            "InterventionBrowseLeafName": "Interleukin-2",
                            "InterventionBrowseLeafAsFound": "Magnetic Resonance Imaging",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M3722",
                            "InterventionBrowseLeafName": "Analgesics",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20476",
                            "InterventionBrowseLeafName": "Analgesics, Non-Narcotic",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M21040",
                            "InterventionBrowseLeafName": "Anti-HIV Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25118",
                            "InterventionBrowseLeafName": "Anti-Retroviral Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M4004",
                            "InterventionBrowseLeafName": "Antiviral Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3904",
                            "InterventionBrowseLeafName": "Anti-Infective Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infe",
                            "InterventionBrowseBranchName": "Anti-Infective Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Analg",
                            "InterventionBrowseBranchName": "Analgesics"
                        }
                    ]
                }
            }
        }
    }
}